Perhaps just one, perhaps the main, reason TEVA will acquire CEPH.
Looking at CEPH's pipeline, I think TEVA would consider cinquil as the best longer duration asset cause of their strong involvement in the respiratory arena and the potential for this drug. No doubt they see good oportunity in the stem cell area as they have already established a JV with a loacal company in the area ( http://www.gamida-cell.com/press_item.asp?ID=48 ). So far, interim data from phase IIa trial in CHF for Mesoblat's revascor were clean (safety) and stat-sig better than control in serious adverse cardiac events.
According to Teva's presentation at RBC, you were right - revascor for CHF was highlighted as one of the most promising opportunities in the brand pipeline.
News 
Market Data 
Discover 
